Homocysteine-induced vascular dysregulation is mediated by the NMDA receptor

Vascular Medicine

Volumn 10, Issue 3, 2005, Pages 215-223

  Qureshi, Irfan ^a,b   Chen, Hongjiang ^a,b   Brown, Aliza T ^a,b   Fitzgerald, Ryan ^a,b   Zhang, Xingjian ^a,b   Breckenridge, Julie ^a   Kazi, Rafi ^a   Crocker, Amy J ^a   Stühlinger, Markus C ^c   Lin, Kenneth ^c   Cooke, John P ^c   Eidt, John F ^a,b   Moursi, Mohammed M ^a,b  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cells; Homocysteine; Nitric oxide; Peripheral vascular disease; Smooth muscle

Indexed keywords

BETA ACTIN; DIZOCILPINE; GELATINASE B; HOMOCYSTEINE; INTERLEUKIN 1BETA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2C; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2D; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTERY INTIMA PROLIFERATION; ARTICLE; ATTENUATION; BRAIN BLOOD VESSEL; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; HYPERHOMOCYSTEINEMIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; SMOOTH MUSCLE FIBER; THORACIC AORTA; TIME; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; AORTA, THORACIC; ARGININE; CELL CULTURE TECHNIQUES; CELL MOVEMENT; CELL PROLIFERATION; HOMOCYSTEINE; INTERLEUKIN-1; MATRIX METALLOPROTEINASE 9; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER;

EID: 26944437990     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x05vm626oa     Document Type: Article

References (50)

1. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study (ACAS). Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 1421-28.
2. North American Symptomatic Carotid Endarterectomy Trial Collaborators (NASCET). Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325: 445-53.
3. Healy DA, Zeirler RE, Nicholls SC et al. Long-term follow-up and clinical outcome of carotid restenosis. J Vasc Surg 1989; 10: 662-69.
4. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62.
5. McCully KS. The homocysteine revolution. New Canaan, CT: Keats, 1997.
6. Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000; 72: 315-23.
7. Tsai JC, Perrella MA, Yoshizumi M et al. Promotion of vascular smooth muscle cell growth by homocysteine a link to atherosclerosis. Proc Natl Acad Sci U S A 1994; 91: 6369-73.
8. Ikeda U, Ikeda M, Minota S, Shimada K. Homocysteine increases nitric oxide synthesis in cytokine-stimulated vascular smooth muscle cells. Circulation 1999; 99: 1230-35.
9. Chen C, Halkos ME, Surowiec SM, Conklin BS, Lin PH, Lumsden AB. Effects of homocysteine on smooth muscle cell proliferation in bovine cell culture artery perfusion culture models. J Surg Res 2000; 88: 26-33.
10. Li J, Chai S, Tang C, Du J. Homocysteine potentiates calcification of cultured rat aortic smooth muscle cells. Life Sci 2003; 74: 451-61.
11. Schroecksnadel K, Frick B, Wirleitner B, Winkler C, Schennach H, Fuchs D. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 2004; 5: 107-18.
12. Dalton ML, Gadson Jr PF, Wrenn RW, Rosenquist TH. Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J 1997; 11: 703-11.
13. Zhang D, Lipton S. L-homocysteic acid selectively activates N-methyl-D-aspartate receptors of rat retinal ganglion cells. Neurosci Lett 1992; 139: 173-77.
14. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489-509.
15. Boger RH, Sydow K, Borlak J et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87: 99-105.
16. Stühlinger MC, Oka RK, Graf EE et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia. Role of asymmetric dimethylarginine. Circulation 2003; 108: 933-38.
17. Stühlinger MC, Tsao PS, Her J-H, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the NO synthase pathway - role of asymmetric dimethylarginine. Circulation 2001; 104: 2569-75.
18. Scott-Burden T, Schini VB, Elizondo E, Junquero DC, Vanhouette PM. Platelet-derived growth factor suppresses and fibroblast growth factor enhances cytokine-induced production of nitric oxide by cultured smooth muscle cells. Effects on cell proliferation. Circ Res 1992; 71: 1088-100.
19. Lin SJ, Yen HT, Chen YH, Ku HH, Lin FY, Chen YL. Expression of interleukin-1 beta and interleukin-1 receptor antagonist in oxLDL-treated human aortic smooth muscle cells in the neointima of cholesterol-fed endothelia-denuded rabbits. J Cell Biochem 2003; 88: 836-47.
20. Southgate KM, Davies M, Booth RFG, Newby AC. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J 1992; 288: 93-99.
21. Newby AC, Southgate KM, Davies M. Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Res Cardiol 1994; 89: 59-70.
22. Yoshioka A, Ikegaki N, Williams M, Pleasure D. Expression of N-methyl-D-aspartate (NMDA) and non-NMDA glutamate receptor genes in neuroblastoma, medulloblastoma, and other cell lines. J Neurosci Res 1996; 46: 164-78.
23. Stühlinger MC, Abbasi F, Chu FW et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-26.
24. Galis ZS, Johnson C, Godin D et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 2002; 91: 852-59.
25. Furman C, Luo Z, Walsh K et al. Systemic tissue inhibitor of metalloproteinase-1 gene delivery reduces neointimal hyperplasia in balloon injured rat carotid arteries. FEBS Lett 2002; 531: 122-26.
26. Nathe TJ, Deou J, Walsh B, Bourns B, Clowes AW, Daum G. Interleukin-1beta inhibits expression of p21 (WAFI/CIP1) and p27 (KIP1) and enhances proliferation in response to platelet-derived growth factor-BB in smooth muscle cells. Arterioscler Thromb Vasc Biol 2002; 22: 1293-98.
27. Molloy KJ, Thompson MM, Schwalbe EC, Bell PR, Naylor AR, Loftus IM. Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively. Am J Cardiol 2004; 94: 144-46.
28. Formato M, Farina M, Spirito R et al. Evidence for a pro-inflammatory and proteolytic environment in plaques from endarterectomy segments of human carotid arteries. Arterioscler Thromb Vasc Biol 2004; 24: 129-35.
29. Buttery LD, Springall DR, Chester AH et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996; 75: 77-85.
30. Luoma JS, Stralin P, Marklund SL, Hiltunen TP, Sarkioja T, Yla-Herttuala S. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. Arterioscler Thromb Vasc Biol 1998; 18: 157-67.
31. Schwarz S, Zhou GZ. N-methyl-D-aspartate receptors and CNS symptoms of homocystinuria. Lancet 1991; 337: 1226-27.
32. McCully KS. Homocysteine metabolism in scurvy, growth and arteriosclerosis. Nature 1971; 231: 391-94.
33. Omori S, Kodama H, Ikegami T, Mizuhara S, Oura T. Unusual sulfur-containing amino acids in the urine of homocystinuric patients. III Homocysteic acid, homocysteine sulfinic acid, S-(carboxymethylthio)homocysteine, and S-(3-hydroxy-3-carboxy-n-propyl) homocysteine. Physiol Chem Phys 1972; 4: 286-94.
34. Blom H. Consequences of homocysteine export and oxidation in the vascular system. Semin Thromb Hemost 2000; 26: 227-32.
35. Chen P, Poddar R, Tipa EV et al. Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv Enzyme Reg 1999; 39: 93-109.
36. Hongjiang C, Fitzgerald R, Brown AT et al. Identification of a homocysteine receptor in the peripheral endothelium and its role in proliferation. J Vasc Surg 2005; 41: 853-60.
37. Southern F, Eidt J, Drouilhet J et al. Increasing levels of dietary homocysteine with carotid endarterectomy produced proportionate increases in plasma homocysteine and intimal hyperplasia. Atherosclerosis 2001; 158: 129-38.
38. Hebert MJ, Gullans SR, Mackenzie HS, Brady HR. Apoptosis of endothelial cells is associated with paracrine induction of adhesion molecules. Am J Pathol 1998; 152: 523-32.
39. Koga T, Claycombe K, Meydani M. Homocysteine increases monocyte and T-cell adhesion to human aortic endothelial cells. Atherosclerosis 2002; 161: 365-74.
40. Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 1990; 275: 87-90.
41. Schini VB, Junquero DC, Scott-Burden T, Vanhoutte PM. Interleukin-1β induces the production of an L-arginine-derived relaxing factor from cultured smooth muscle cells from rat aorta. Biochem Biophys Res Commun 1991; 176: 114-21.
42. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide sythesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068-74.
43. Hassid A, Arabshari H, Bourcier T, Dhaunsi GS, Matthews C. Nitric oxide selectively amplifies FGF-2-induced mitogenesis in primary rat aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 1994; 267: H1040-48.
44. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-41.
45. Yue TL, Wang XK, Olson B, Fenerstein G. Interleukin-1 beta (IL-1 beta) induces transforming growth factor beta (TGF-beta 1) production by rat aortic smooth muscle cells. Biochem Biophys Res Commun 1994; 204: 1186-92.
46. de Frutos T, de Miguel LS, Garcia-Duran M et al. NO from smooth muscle cells decreases NOS expression in endothelial cells: role of TNF-α. Am J Physiol 1999; 277: H1317-25.
47. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271: C1424-37.
48. Wedgwood S, Black SM. Molecular mechanisms of nitric oxide-induced growth arrest and apoptosis in fetal pulmonary arterial smooth muscle cells. Nitric Oxide 2003; 9: 201-10.
49. Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 1557-64.
50. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci U S A 2002; 99: 13527-32.